Therapeutically targeting ion channels in nociceptor neurons may be a promising strategy to manage osteoarthritis pain.
Paul DeCaen, Ph.D., associate professor of Pharmacology, was senior author of the study.
Nociceptor neurons transmit pain signals to the brain using electrical currents generated by voltage-gated sodium channels; when overactive, those channels are commonly observed in cases of osteoarthritis and other aberrant pain conditions.
Targeting the sodium channels to improve osteoarthritis pain management is been explored as a potential therapeutic strategy. Previous work from the DeCaen laboratory demonstrated that a metabolite of tamoxifen, an estrogen receptor modulator, binds to the intracellular exit of the channel, underscoring it’s therapeutic potential.
Despite the clear need, efforts in developing novel sodium channel blockers into real therapies has been challenging, according to DeCaen.
“Repurposing tamoxifen metabolites, commonly used to treat breast cancer, presents an alternative strategy which can bypass phase one clinical trials,” DeCaen said.
In the current study, DeCaen’s team administered a tamoxifen metabolite to mice that had been genetically modified to develop osteoarthritis symptoms. They found the drug bound to two intracellular receptor sites in sodium channels, blocking the entry of ions using a “bind and plug” mechanism and inhibiting sodium channels in inflamed, overactivated nociceptor neurons responsible for osteoarthritic pain.
“To our knowledge, clinical efficacy of tamoxifen metabolites for osteoarthritic pain treatment is untested. Yet many years of oncology clinical data significantly de-risks their use, which may lower overall development costs for their use to treat osteoarthritic pain,” DeCaen said.